Non-expanded adipose stromal vascular fraction cell therapy for multiple sclerosis. J Transl Med 7:29

Medistem Inc, San Diego, CA, USA.
Journal of Translational Medicine (Impact Factor: 3.93). 05/2009; 7(1):29. DOI: 10.1186/1479-5876-7-29
Source: PubMed


The stromal vascular fraction (SVF) of adipose tissue is known to contain mesenchymal stem cells (MSC), T regulatory cells, endothelial precursor cells, preadipocytes, as well as anti-inflammatory M2 macrophages. Safety of autologous adipose tissue implantation is supported by extensive use of this procedure in cosmetic surgery, as well as by ongoing studies using in vitro expanded adipose derived MSC. Equine and canine studies demonstrating anti-inflammatory and regenerative effects of non-expanded SVF cells have yielded promising results. Although non-expanded SVF cells have been used successfully in accelerating healing of Crohn's fistulas, to our knowledge clinical use of these cells for systemic immune modulation has not been reported. In this communication we discuss the rationale for use of autologous SVF in treatment of multiple sclerosis and describe our experiences with three patients. Based on this rationale and initial experiences, we propose controlled trials of autologous SVF in various inflammatory conditions.

Download full-text


Available from: Boris Minev, Oct 02, 2015
33 Reads
  • Source
    • "Currently, not enough information is known about SVF to determine if such a product with a mixed cellular composition offers a therapeutic advantage or disadvantage for the intended applications . Culture-expanded MSCs (both bmMSCs and aMSCs) are the type predominantly used in the rodent model literature, however more recent rodent studies have started to explore the therapeutic potential of the SVF cellular product with promising results (Riordan et al., 2009; Yasuda et al., 2012). "
    [Show abstract] [Hide abstract]
    ABSTRACT: Stem cell therapy is an innovative field of scientific investigation with tremendous potential for clinical application that holds promise for the treatment of a variety of diseases in veterinary medicine. Based on the known desirable properties of mesenchymal stem cells, the therapy has potential for treatment of both acute kidney injury and chronic kidney disease in cats. This review details terminology commonly used in this field of study, sources of mesenchymal stem cells and their proposed mechanism of action particularly as it relates to renal repair. Studies performed in rodent models of chronic kidney disease and feline clinical trial results are also summarized with the aim of providing an overview of the current status of this treatment modality and its potential for the future. Copyright © 2015 Elsevier Ltd. All rights reserved.
    The Veterinary Journal 04/2015; 204(3). DOI:10.1016/j.tvjl.2015.04.007 · 1.76 Impact Factor
  • Source
    • "The therapeutic rationale for use of stromal vascular fraction (SVF) cells and the high content of native multi-potent adipose-derived stem/stromal cells (ASCs) within the SVF has gained recent substantial clinical interest. SVF typically has been reported to contain a heterogeneous population of cells including preadipocytes, ASCs, endothelial progenitor cells (EPCs), T-regulatory cells and M2 macrophages [1]. The method of harvesting, the site and separation of these cells may result in differing proportions of these populations. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Introduction Chronic migraines and tension-type headaches are debilitating diseases affecting 1.4 to 2.2% of the population with both quality of life and economic implications. To date, the pain associated with migraine and tension-type headaches has been controlled with a range of medications, with varying levels of success. In addition, the side-effect profile of these medications, as well as their potential for addiction, has been a cause for concern for both patients and physicians. Case presentations Four women with long histories of migraine or frequent tension-type headache that meet the International Classification of Headache Disorders criteria for Chronic Migraine or Tension-type Headaches were given a systemic treatment(s) of autologous stromal vascular fraction or autologous ‘StroMed’ isolated from lipoaspirate. StroMed is stromal vascular fraction cells prepared by ultrasonic cavitation. Two of the four patients, both of whom are Arab women aged 40 and 36 years, ceased having migraines after 1 month, for a period of 12 to 18 months. The third patient, a Slavic woman aged 43 years, had a significant decrease in the frequency and severity of migraines with only seven migraines over 18 months. The fourth patient, an Asian woman aged 44 years, obtained a temporary decrease for a period of a month and was retreated 18 months later and has been free of migraines to date for 1 month. Pain medication was typically reduced from prescribed opioid analgesia to non-steroidal anti-inflammatory drugs and paracetamol. Conclusions This case series is the first to provide evidence of the efficacy of autologous StroMed and stromal vascular fraction in the treatment of migraine and tension-type headache. The treatment of this disease by stromal vascular fraction adds a new dimension to its clinical applicability and suggests a relatively simple treatment that may help address the symptoms of the disease. Given what is known about the components of the stromal vascular fraction and how they act, the information presented in this case series may also further our knowledge of the etiology and pathophysiology of migraine and tension-type headaches. This treatment is simple, looks to be extremely effective and has been life changing for these patients.
    Journal of Medical Case Reports 06/2014; 8(1):237. DOI:10.1186/1752-1947-8-237
  • Source
    • "The solution then undergoes centrifugation, separating it into adipose, fluid, and stromal vascular fraction (SVF) layers [44]. The SVF consists of preadipocytes, MSCs, endothelial progenitor cells, T and B cells, mast cells, and adipose tissue macrophages [45]. The SVF layer is seeded into demineralized bone grafts and incubated for 36 hours, allowing MSCs to adhere to the demineralized bone. "
    [Show abstract] [Hide abstract]
    ABSTRACT: Advances in the field of stem cell technology have stimulated the development and increased use of allogenic bone grafts containing live mesenchymal stem cells (MSCs), also known as cellular bone matrices (CBMs). It is estimated that CBMs comprise greater than 17% of all bone grafts and bone graft substitutes used.
    The spine journal: official journal of the North American Spine Society 06/2014; 14(11). DOI:10.1016/j.spinee.2014.05.024 · 2.43 Impact Factor
Show more